Real-World data could unlock better breast cancer treatment choices
NCT ID NCT07647042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at medical records from 750 people with a common type of early breast cancer (HR+/HER2-). It aims to understand how doctors treat these patients in real life, especially after newer targeted drugs called CDK4/6 inhibitors became available. By analyzing treatment patterns, genetic testing use, and patient outcomes, the study hopes to improve care for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal how well new targeted therapies work in everyday practice, helping doctors choose the best treatments for early breast cancer.
- What could go wrong
- This is an observational study using existing medical records, so it cannot prove cause and effect. Results may be limited by incomplete data or differences in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?